What's Happening?
Human metapneumovirus (HMPV) is currently affecting several U.S. states, including California and New Jersey, with a notable increase in cases. HMPV is a respiratory virus that can cause both upper and lower respiratory diseases. According to the Centers
for Disease Control and Prevention (CDC), there is no vaccine or specific antiviral treatment available for HMPV. The virus was first identified in 2001, but recent spikes in cases have not been seen since an outbreak in April 2025. The National Respiratory and Enteric Virus Surveillance System reports that HMPV accounts for over 5% of weekly positive tests for respiratory viruses, a rise from the previous week. In New Jersey, the surge in HMPV cases, along with RSV, COVID-19, and flu cases, has led to increased emergency medical care visits. In Northern California, high levels of HMPV have been detected in wastewater. Symptoms of HMPV include cough, nasal congestion, fever, and shortness of breath, which can progress to bronchitis or pneumonia. The virus is seasonal, circulating from winter through spring, with an incubation period of three to six days.
Why It's Important?
The rise in HMPV cases is significant due to the absence of a vaccine or specific treatment, posing a public health challenge. The virus primarily affects younger children and adults over 65, who are at higher risk of severe illness. The increase in cases could strain healthcare systems, particularly emergency services, as seen in New Jersey. The detection of HMPV in wastewater highlights the potential for widespread community transmission. Public health officials emphasize preventive measures such as hand hygiene and avoiding contact with sick individuals to mitigate the spread. The situation underscores the need for continued surveillance and research to develop effective vaccines and treatments for HMPV.
What's Next?
Public health authorities are likely to continue monitoring HMPV cases closely, especially in states experiencing significant outbreaks. Efforts may focus on increasing public awareness about preventive measures and symptoms to reduce transmission. Healthcare providers might prepare for potential increases in patient load, particularly in emergency departments. Research into vaccine development and antiviral treatments for HMPV could gain momentum, given the current lack of specific medical interventions. The situation may prompt discussions on improving respiratory virus surveillance and response strategies to better manage future outbreaks.
